Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A1 | P30531 | 2/20 | 0.50 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.50 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.50 |
| ▸ | SLC6A12 | P48065 | 2/20 | 0.50 |
| ▸ | SLC6A11 | P48066 | 2/20 | 0.50 |
| ▸ | SLC6A13 | Q9NSD5 | 2/20 | 0.50 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.50 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.50 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.50 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.47 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.47 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.47 |
| ▸ | ITGA5 | P08648 | 2/20 | 0.47 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.47 |
| ▸ | ITGAV | P06756 | 1/20 | 0.47 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.47 |
| ▸ | ITGAL | P20701 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4532111 | 0.80 | ITGB1 (0.50) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 | |
| SCHEMBL2723878 | 0.80 | ITGB1 (0.50) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 | |
| SCHEMBL6921399 | 0.78 | — | — | |
| SCHEMBL17342284 | 0.78 | — | — | |
| SCHEMBL4400125 | 0.76 | POLB (0.45) | ALDH1A1POLBMAPTTDP1TSHR | |
| SCHEMBL16109535 | 0.75 | — | — | |
| SCHEMBL630436 | 0.75 | ITGB1 (0.54) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 | |
| SCHEMBL26064924 | 0.75 | — | — | |
| SCHEMBL7837579 | 0.74 | BRD4 (0.39) | IRAK4PDCD1CD274 | |
| SCHEMBL13575606 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230391786-A1 | cGAS INHIBITORS | ELI LILLY AND COMPANY | 2023-12-07 | — | — | US | disclosed |
| WO-2023235809-A1 | CGAS INHIBITORS | ELI LILLY AND COMPANY (US) | 2023-12-07 | — | — | WO | disclosed |
| US-9023146-B2 | Oxidizing agents on pigments | EMPIRE TECHNOLOGY DEVELOPMENT LLC (US) | 2015-05-05 | — | — | US | disclosed |
| CN-103917545-A | BTK inhibitors | MERCK SHARP & DOHME | 2014-07-09 | — | — | CN | disclosed |
| US-20140083323-A1 | OXIDIZING AGENTS ON PIGMENTS | EMPIRE TECHNOLOGY DEVELOPMENT LLC (US) | 2014-03-27 | — | — | US | disclosed |
| EP-1019400-B1 | BENZO(5,6)CYCLOHEPTAPYRIDINE COMPOUNDS USEFUL AS FARNESYL PROTEIN TRANSFERASE INHIBITORS | SCHERING CORP (US) | 2004-08-11 | — | — | EP | disclosed |
| CN-1119345-C | Benzo (5,6) cycloheptapyridine compounds useful as farnesyl protein transferase inhibitors | SCHERING CORP (US) | 2003-08-27 | — | — | CN | disclosed |
| CN-1267302-A | Benzo (5.6) cycloheptopyridine compounds useful as farnesyl protein transferase inhibitors | SCHERING CORP (US) | 2000-09-20 | — | — | CN | disclosed |
| EP-1019400-A1 | BENZO(5,6)CYCLOHEPTAPYRIDINE COMPOUNDS USEFUL AS FARNESYL PROTEIN TRANSFERASE INHIBITORS | SCHERING CORPORATION (US) | 2000-07-19 | — | — | EP | disclosed |
| US-5939416-A | INHIBIT RAS FUNCTION, USE FOR TREATING TUMOR CELLS EXPRESSING AN ACTIVATED RAS ONCOGENE IN MAMMALS | SCHERING CORPORATION (US) | 1999-08-17 | — | — | US | disclosed |
| WO-1998057970-A1 | BENZO(5,6)CYCLOHEPTAPYRIDINE COMPOUNDS USEFUL AS FARNESYL PROTEIN TRANSFERASE INHIBITORS | SCHERING CORPORATION (US) | 1998-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230391786-A1 | cGAS INHIBITORS | CGAS, STING1, TBK1 | SLC6A1 4390/4885GABRA5 4369/4885GABRB2 3146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.